Neven activiteiten van Sabine Linn

Family Name:                   

Linn

Christian names:             

Sabine Charlotte

BIG number:                     

99032942301

Working address:             

Dept. of Medical Oncology

Netherlands Cancer Institute

Plesmanlaan 121

1066 CX  Amsterdam

The Netherlands

Telephone:                       

+31 20 5129111

Fax:                                   

+31 20 5122572                                               

Advisory boards and consultancies

2012 – present                

Function: Member Scientific Advisory Board

Organization: Cergentis, a spin-off company for targeted amplification of complete genes, The Netherlands

Personal income: No

2016                                      

Function: Member Lynparza (Olaparib) AstraZeneca Global Advisory Board

Organization: AstraZeneca

Personal income: No

2016 – 2017                     

Function: Member IBM Watson Health Oncology Global Advisory Board

Organization: IBM, Boston, MA, USA

Personal income: No

Educational and scientific committees

2003 – 2020                       

Function: Member of the NKI-AVL Organizing Committee for Continuing Medical Education Program for Dutch Medical Oncologists “DONAMO (DOorlopende NAscholing Medische Oncologie)”

Organization: Netherlands Cancer Institute, Amsterdam, Netherlands

Personal income: No

2007 – 2015                       

Function: Member of the Dutch Society for Medical Oncology (NVMO) Advisory Board for the Dutch Institute for Healthcare Improvement (CBO) Breast Cancer Guidelines

Organization: Dutch Institute for Healthcare Improvement (CBO)

Personal income: No

2008 – 2013                       

Function: Chair Working Group (neo)adjuvant systemic therapy of Borstkanker Onderzoek Groep (BOOG) (Dutch Breast Cancer Trialists’ Group)

Organization: Dutch Breast Cancer Trialists’ Group

Personal income: No

2013 – 2019                      

Function: Member of Program Committee of Dutch and Flemish Annual Oncology Days (NVMO Oncologiedagen Nederland en Vlaanderen)

Organization: NVMO (Nederlandse Vereniging voor Medische Oncologie)

Personal income: No

2014 – present                

Function: Member Committee on Personalised Medicine

Organization: ZonMw, The Netherlands

Personal income: No

2015 - present                 

Member Editorial Board of Breast Cancer Research

Organization: Springer Nature

Personal income: No

2015                                      

Function: Member Scientific Advisory Group

Organization: European Medicines Agency (EMA) London, UK

Personal income: No

2016 – 2017                      

Function: Member RiskAp Expert Group on breast cancer screening

Organization: German Federal Ministry of Education and Research

Personal income: No

2016 – 2017                    

Function: Member Scientific Evaluation Committee Institut National du Cancer, France

Organization: Institut National du Cancer (INCA), Paris, France

Personal income: No

2016 – 2017                       

Function: Member Expert Review Panel CRUK and EPSRC Cancer Imaging Centres (Oxford University, Cambridge University, King’s College London/University College London, The Institute of Cancer Research)

Organization: Cancer Research United Kingdom (CRUK)

Personal income: No

2016 – 2017                       

Function: Member IMPAKT 2017 Scientific Committee, Brussels, Belgium

Organization: ESMO (European Society of Medical Oncology) and BIG (Breast International Group)

Personal income: No

2016 – 2018                       

Function: Member ESMO 2018 scientific subcommittee breast cancer, early

Organization: ESMO (European Society of Medical Oncology)

Personal income: No

2017 – 2019                       

Function: Co-chair (with Alberto Bardelli) ESMO-EACR 2019 scientific subcommittee Translational Research

Organization: ESMO (European Society of Medical Oncology)

Personal income: No

2017 – 2020                       

Function: Member evaluation board of the panel LS4 “Physiology, Pathophysiology and Endocrinology” for European Research Council  Consolidator Grants (CoG) in 2018, and 2020

Organization: European Commission

Personal income: Yes, > 2,200 Euro/year

2018 - present                  

Faculty ENDEAVOR workshops for European future breast cancer leaders in the field

2021 – present                

Function: Member VIDI committee Dutch Research Council (NWO)

Organisation: Dutch Research Council (NWO)

Personal income: yes, < 2,200 euro/year

2022 – present                 

Member Health Council of the Netherlands – Independent scientific advisory body for government and parliament

Dr. Sabine Linn is a professor of translational oncology focusing on breast cancer at Utrecht University, The Netherlands. Linn received her medical degree (1991, cum laude) at the State University Leiden, The Netherlands, and her internal medicine board certification (2000) at the University Medical Center Utrecht, The Netherlands. She earned her PhD (1998) on the subject of multidrug resistance in solid tumors from the Free University of Amsterdam under supervision of prof. Dr H.M. Pinedo.
She was awarded a Dutch Cancer Society Research Fellowship in 2000 and developed two conditional knock-out mouse models, one for non-small cell lung cancer and one for small cell lung cancer, respectively, in close collaboration with Dr Ralph Meuwissen in the laboratory of prof. Dr A.J. Berns at the Netherlands Cancer Institute, Amsterdam, The Netherlands. From 2001 to 2002 she was a postdoctoral research fellow in the laboratories of prof. Dr P.O. Brown, and prof. Dr M. van de Rijn, at Stanford University Medical School, Stanford, CA, where she contributed to the development of a molecular classification for soft tissue sarcomas. She returned to the Netherlands Cancer Institute in Amsterdam, where she earned her medical oncology certification (2002-2005) and became a senior staff member of the Division of Medical Oncology (2003).
Since 2005 she has also been a group leader at the Division of Molecular Pathology at the Netherlands Cancer Institute where she and her research group focus on the molecular dissection of breast cancer by differential drug sensitivity. To further develop this research line Dr. Linn was awarded a Dutch Cancer Society Clinical Research Award in 2006. From 2008-2012, Dr Linn served as chair of the Working Group on (neo)adjuvant systemic therapy of the Dutch Breast Cancer Trialists' Group (BOOG).